Most synonymous allelic variants in HIV tat are not silent.

Codon usage HIV RNA stability Silent Synonymous Tat Variant

Journal

Genomics
ISSN: 1089-8646
Titre abrégé: Genomics
Pays: United States
ID NLM: 8800135

Informations de publication

Date de publication:
05 2023
Historique:
received: 19 11 2022
revised: 12 02 2023
accepted: 03 03 2023
medline: 25 5 2023
pubmed: 10 3 2023
entrez: 9 3 2023
Statut: ppublish

Résumé

The genetic code has degenerate codons that produce no change in the translated protein sequence and are generally thought to be silent. However, some synonymous variants are clearly not silent. Herein, we questioned the frequency of non-silent synonymous variants. We tested how random synonymous variants in the HIV Tat transcription factor effect transcription of an LTR-GFP reporter. Our model system has the advantage of directly measuring the function of the gene in human cells. Approximately, 67% of synonymous variants in Tat were non-silent, either having reduced activity or were full loss-of-function alleles. Eight mutant codons had higher codon usage than wild type, accompanied by reduced transcriptional activity. These were clustered on a loop in the Tat structure. We conclude that most synonymous Tat variants are not silent in human cells, and 25% are associated with changes in codon usage, likely effecting protein folding.

Identifiants

pubmed: 36893872
pii: S0888-7543(23)00047-2
doi: 10.1016/j.ygeno.2023.110603
pmc: PMC10257815
mid: NIHMS1903390
pii:
doi:

Substances chimiques

Codon 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

110603

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM121325
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI116411
Pays : United States

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest CJG, JIR, and MRS authors work for Heligenics that uses the GigaAssay technology for commercial drug development, drug discovery and diagnostics. There is a potential conflict of interest as the impact of the non-silent variant rate could benefit Heligenics pursuit to produce data that improves genetic testing.

Références

Genomics. 2022 Jul;114(4):110439
pubmed: 35905834
BMC Cancer. 2021 Apr 9;21(1):388
pubmed: 33836673
Genome Biol Evol. 2021 Sep 1;13(9):
pubmed: 34132772
Biochem Soc Trans. 2018 Aug 20;46(4):937-944
pubmed: 30065107
Cell. 2015 Mar 12;160(6):1111-24
pubmed: 25768907
Front Microbiol. 2021 Jan 11;11:619430
pubmed: 33505387
Cell. 2014 Mar 13;156(6):1324-1335
pubmed: 24630730
Data Brief. 2022 Sep 28;45:108641
pubmed: 36426049
Nature. 2022 Mar;603(7900):335-342
pubmed: 35236983
EMBO J. 1984 Dec 1;3(12):2895-8
pubmed: 6396082
Am J Hum Genet. 2008 Jan;82(1):188-93
pubmed: 18179898
Trends Genet. 2017 Apr;33(4):283-297
pubmed: 28292534
Nat Struct Mol Biol. 2014 Dec;21(12):1100-5
pubmed: 25420103
Bioinformatics. 2016 Jun 15;32(12):1914-6
pubmed: 27153700
PLoS Genet. 2018 Aug 27;14(8):e1007615
pubmed: 30148850
Cell Commun Signal. 2020 Sep 9;18(1):145
pubmed: 32907610
Trends Genet. 2014 Jul;30(7):308-21
pubmed: 24954581
Front Microbiol. 2021 Mar 16;12:606087
pubmed: 33796084
J Mol Biol. 1995 Apr 7;247(4):529-35
pubmed: 7723010
PLoS Comput Biol. 2017 May 5;13(5):e1005531
pubmed: 28475588
Science. 2010 Sep 17;329(5998):1534-7
pubmed: 20847274
Leukemia. 2020 Oct;34(10):2673-2687
pubmed: 32555368
Proc Natl Acad Sci U S A. 1983 Feb;80(3):687-91
pubmed: 6338495
Nature. 2022 Jun;606(7915):725-731
pubmed: 35676473
PLoS One. 2016 Jan 04;11(1):e0146375
pubmed: 26727272
Bioessays. 2023 Apr;45(4):e2200191
pubmed: 36789580
Proc Natl Acad Sci U S A. 1961 Oct 15;47:1588-602
pubmed: 14479932
Clin Chem. 2021 Oct 1;67(10):1384-1394
pubmed: 34459892
BMC Med Genet. 2019 Dec 9;20(Suppl 2):190
pubmed: 31815613
Nucleic Acids Res. 2003 Jul 1;31(13):3406-15
pubmed: 12824337
Science. 2009 Apr 10;324(5924):255-8
pubmed: 19359587
Proc Natl Acad Sci U S A. 2022 Apr 26;119(17):e2112677119
pubmed: 35439059
Nucleic Acids Res. 2016 Dec 15;44(22):10898-10911
pubmed: 27466388
Nat Struct Mol Biol. 2013 Feb;20(2):237-43
pubmed: 23262490
Pigment Cell Melanoma Res. 2015 Nov;28(6):673-84
pubmed: 26300548
Antimicrob Agents Chemother. 2021 May 18;65(6):
pubmed: 33820762
Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3528-3534
pubmed: 32015130
Mol Biol Evol. 2016 Jun;33(6):1542-53
pubmed: 26908584
Nat Rev Genet. 2011 Aug 31;12(10):683-91
pubmed: 21878961
Am J Hum Genet. 2022 Dec 1;109(12):2105-2109
pubmed: 36459978
Acta Virol. 2021;65(2):173-180
pubmed: 34130468
Nat Commun. 2019 Jun 12;10(1):2569
pubmed: 31189880

Auteurs

Christopher J Giacoletto (CJ)

Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, 4505 S. Maryland Parkway, Las Vegas, Nevada 89154, USA; School of Life Sciences, University of Nevada, Las Vegas, 4505 S. Maryland Parkway, Las Vegas, Nevada 89154, USA; Heligenics Inc., 833 Las Vegas Blvd. North, Suite B, Las Vegas, NV 89101, USA.

Ronald Benjamin (R)

Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, 4505 S. Maryland Parkway, Las Vegas, Nevada 89154, USA; School of Life Sciences, University of Nevada, Las Vegas, 4505 S. Maryland Parkway, Las Vegas, Nevada 89154, USA.

Hong-Wen Deng (HW)

Center for Bioinformatics and Genomics, Department of Global Biostatistics and Data Science, School of Public Health and Tropical Medicine, Tulane University, New Orleans 70112, USA.

Jerome I Rotter (JI)

The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA; Heligenics Inc., 833 Las Vegas Blvd. North, Suite B, Las Vegas, NV 89101, USA.

Martin R Schiller (MR)

Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, 4505 S. Maryland Parkway, Las Vegas, Nevada 89154, USA; School of Life Sciences, University of Nevada, Las Vegas, 4505 S. Maryland Parkway, Las Vegas, Nevada 89154, USA; Heligenics Inc., 833 Las Vegas Blvd. North, Suite B, Las Vegas, NV 89101, USA. Electronic address: martin.schiller@unlv.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH